Literature DB >> 30662679

Tuft1 promotes thyroid carcinoma cell invasion and proliferation and suppresses apoptosis through the Akt-mTOR/GSK3β signaling pathway.

Huifang Liu1, Jing Zhu1, Ziming Mao1, Guangya Zhang1, Xi Hu1, Fengling Chen1.   

Abstract

In this study, we aimed to investigate the biological functions of Tuftelin 1 (Tuft1) in thyroid carcinoma (TC) and determine its underlying molecular mechanism. We found that the expression of Tuft1 was significantly upregulated in TC tissues. Using TC tissue microarrays (n = 154), we found that Tuft1 expression was closely related with the overall survival (OS) and disease-free survival (DFS) of TC patients. Knockdown of Tuft1 in TPC-1 and SW579 cells suppressed the invasion and proliferation of TC cells and increased the apoptosis of TC cells. In vivo, knockdown of Tuft1 attenuated tumor growth and suppressed the phosphorylation of Akt, mTOR, and GSK3β signaling. Addition of recombinant Tuft1 protein (rTuft1) to TC cells increased the phosphorylation of Akt, mTOR, and GSK3β signaling. An mTOR inhibitor (Dactolisib) abrogated rTuft1 protein-induced TC cell invasion, proliferation, and apoptosis inhibition, whereas a GSK3β inhibitor (CHIR-98014) only abrogated rTuft1 protein-induced proliferation and apoptosis inhibition. These results suggest that Tuft1 promotes TC cell invasion and proliferation, and suppresses apoptosis through the Akt-mTOR or Akt-GSK3β signaling pathway. In the future, Tuft1 may serve as a potential therapeutic target for TC.

Entities:  

Keywords:  Akt-mTOR/GSK3β; Tuft1; apoptosis; invasion; proliferation; thyroid carcinoma

Year:  2018        PMID: 30662679      PMCID: PMC6325505     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  6 in total

1.  Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical Cancer.

Authors:  Jing Chen; Sheng Wu; Jue Wang; Yu Sha; Yong Ji
Journal:  Reprod Sci       Date:  2022-01-24       Impact factor: 2.924

2.  Tuftelin and HIFs expression in osteogenesis.

Authors:  Jan Bobek; Veronika Oralova; Adela Kratochvilova; Ivana Zvackova; Herve Lesot; Eva Matalova
Journal:  Histochem Cell Biol       Date:  2019-09-13       Impact factor: 4.304

3.  Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma.

Authors:  Thea Reinkens; Amelie Stalke; Nicole Huge; Beate Vajen; Marlies Eilers; Vera Schäffer; Oliver Dittrich-Breiholz; Brigitte Schlegelberger; Thomas Illig; Britta Skawran
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

4.  Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.

Authors:  Lei Zhu; Kai X Zhou; Ming Z Ma; Lin L Yao; Yan L Zhang; Hui Li; Chang Du; Xiao M Yang
Journal:  J Immunol Res       Date:  2022-06-19       Impact factor: 4.493

5.  Morphological and Molecular Responses of Lateolabrax maculatus Skeletal Muscle Cells to Different Temperatures.

Authors:  Jingru Zhang; Haishen Wen; Xin Qi; Yonghang Zhang; Ximeng Dong; Kaiqiang Zhang; Meizhao Zhang; Jifang Li; Yun Li
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

6.  Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth.

Authors:  Meng-Na Wu; Wen-Jie Zheng; Wen-Xin Ye; Li Wang; Ying Chen; Jie Yang; Deng-Fu Yao; Min Yao
Journal:  World J Gastroenterol       Date:  2021-06-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.